KLDO
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2021 Q4 | -0.00 | $492,000 | -$18M |
| 2021 Q3 | -0.53 | $104,000 | -$16M |
| 2021 Q2 | -0.58 | $211,000 | -$20M |
| 2021 Q1 | -0.60 | $297,000 | -$24M |
| 2020 Q4 | -0.54 | $243,000 | -$12M |
| 2020 Q3 | -0.65 | $482,000 | -$18M |
| 2020 Q2 | -0.59 | $250,000 | -$17M |
| 2020 Q1 | -0.64 | $0 | -$19M |